AMANDA BIERMAN: Open Payments
NPI 1285199422 · LOUISVILLE, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$687 in 29 payments from 15 companies in 2025. Trend: 2023 $729 · 2024 $413 · 2025 $687
Food & beverage: $687
| Company | Payments | Amount |
|---|---|---|
| Travere Therapeutics, Inc. | 5 | $163 |
| Novartis Pharmaceuticals Corporation | 3 | $83 |
| Alexion Pharmaceuticals, Inc. | 3 | $79 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $74 |
| Fresenius USA Marketing, Inc. | 3 | $62 |
| AstraZeneca Pharmaceuticals LP | 2 | $30 |
| Vifor Pharma, Inc. | 1 | $27 |
| Novo Nordisk Inc | 1 | $26 |
| Calliditas Therapeutics US Inc. | 1 | $24 |
| Genentech USA, Inc. | 1 | $22 |
Products named: ULTOMIRIS, Kerendia, VELPHORO, Fabhalta, FARXIGA, Veltassa, Ozempic, Vanrafia.
Industry payments across KY — which companies pay providers there.
